SCYNEXIS, Inc.
P.O. Box 12878
Research Triangle Park
North Carolina
27709
United States
Tel: 919-544-8600
Fax: 919-544-8697
Website: http://www.scynexis.com/
Email: terry.marquardt@scynexis.com
329 articles about SCYNEXIS, Inc.
-
SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
3/28/2024
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the year ended December 31, 2023.
-
SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference
1/30/2024
SCYNEXIS, Inc. (NASDAQ: SCYX) today announced David Angulo, M.D., President and Chief Executive Officer, will present at Guggenheim’s 6th Annual Biotechnology Conference on Wednesday, February 7 at 11:00 A.M. ET.
-
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
1/29/2024
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second generation fungerp candidate SCY-247.
-
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy
1/5/2024
SCYNEXIS, Inc. today announced the presentation of preclinical efficacy data on its second generation fungerp candidate SCY-247 for the treatment of mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis (AAAM) Conference in Milan, Italy from January 25 – 27, 2024.
-
SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update
11/13/2023
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the third quarter ended September 30, 2023.
-
SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)
10/24/2023
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate, SCY-247, against a broad panel of fungal pathogens.
-
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) October 20-23 in Athens, Greece
10/16/2023
SCYNEXIS, Inc. (NASDAQ: SCYX) today announced the presentation of preclinical data on its second generation fungerp candidate SCY-247 against a broad panel of fungal pathogens, including echinocandin-resistant Candida and Aspergillus, in an oral presentation at the 11th Congress on Trends in Medical Mycology (TIMM) being held in Athens Greece, October 20-23, 2023.
-
SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance
9/28/2023
SCYNEXIS, Inc. is conducting a voluntary nationwide recall of 2 lots of BREXAFEMME® to the consumer level in the US market due to potential cross contamination with a non-antibacterial ß-lactam drug substance in the ibrexafungerp citrate used to manufacture the BREXAFEMME® tablets.
-
SCYNEXIS to Participate in September 2023 Investor Conferences
8/28/2023
SCYNEXIS, Inc., a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, announced that management will participate in the following investor conferences.
-
SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update
8/14/2023
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the second quarter ended June 30, 2023.
-
SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China
7/20/2023
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that China’s National Medical Products Administration (NMPA) has accepted for review a New Drug Application (NDA) for oral ibrexafungerp tablets for the treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (VVC) in the Chinese mainland.
-
SCYNEXIS Announces Achievement of First Development Milestone of $25 Million Under Exclusive License Agreement with GSK
6/21/2023
SCYNEXIS, Inc. today announced the achievement of a $25 million performance-based development milestone under its exclusive license agreement with GSK for ibrexafungerp.
-
SCYNEXIS to Participate in the Maxim Group Virtual Healthcare Conference
6/15/2023
SCYNEXIS, Inc. announced that David Angulo, President and Chief Executive Officer, will take part in a fireside chat at the upcoming Maxim Group Virtual Healthcare Conference on Tuesday, June 20th at 12:30 P.M. ET.
-
SCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets)
5/12/2023
SCYNEXIS, Inc. (NASDAQ: SCYX) today announced the closing of its previously announced exclusive license agreement with GSK plc (LSE/NYSE: GSK) to commercialize the novel antifungal BREXAFEMME® (ibrexafungerp tablets) as a treatment for vulvovaginal candidiasis (VVC) and further develop ibrexafungerp for multiple indications in invasive and life-threatening fungal diseases.
-
SCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate Update
5/11/2023
SCYNEXIS, Inc. announced financial results for the first quarter ended March 31, 2023.
-
SCYNEXIS to Present Ibrexafungerp Data at the 33rd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) April 15-18 in Denmark
4/13/2023
SCYNEXIS, Inc. today announced the presentation of interim data across a diverse array of infection types from its ongoing Phase 3 FURI and CARES studies, as well as the innovative study design of its ongoing Phase 3 MARIO trial of oral ibrexafungerp treatment after an intravenous (IV) echinocandin, at the 33rd Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held in Copenhagen, Denmark, April 15-18, 2023.
-
SCYNEXIS Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
3/31/2023
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the fourth quarter and full year ended on December 31, 2022.
-
GSK will help commercialize Brexafemme (ibrexafungerp), currently approved to treat vaginal yeast infections and vulvovaginal candidiasis (VVC).
-
GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection
3/30/2023
GSK plc (LSE/NYSE: GSK) and SCYNEXIS, Inc. (NASDAQ: SCYX), today announced they have entered into an exclusive licence agreement for Brexafemme (ibrexafungerp tablets), a US FDA approved, first-in-class antifungal for the treatment of vulvovaginal candidiasis (VVC) and for reduction in the incidence of recurrent VVC (RVVC).
-
SCYNEXIS Announces FDA Approval of Second Indication for BREXAFEMME® (ibrexafungerp tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis
12/1/2022
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced that the U.S. Food and Drug Administration (FDA) has approved a second indication for BREXAFEMME® (ibrexafungerp tablets) for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC).